Lymphoma (follicular non-Hodgkin's) - rituximab (TA137)
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)
This guidance replaces NICE technology appraisal guidance 37 issued in March 2002.
The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.
This page was last updated: 31 August 2011
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA137 Rituximab ar gyfer trin lymffoma ffoliglaidd cam III neu IV nad yw'n lymffoma Hodgkin ar ôl ailwaelu neu os nad yw'n ymateb mwyach i driniaeth: deall canllawiau (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.